IDYA Stock — IDEAYA Biosciences, Inc.

Up next

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed May 5, 2026

Equibles Rating

blended score · not investment advice

Overall

Buy

SellHoldBuy

Technical Buy Momentum Strong Sentiment Very Bullish Fundamentals Strong Quant / Vol Very High

Market backdrop VIX 18.2 · elevated Equity put/call 0.71

Technical

price trend

Buy

50 / 200-day cross Golden cross

Price vs 200-day avg +11%

above

Price vs 50-day avg +10%

above

RSI (14) 54

neutral

MACD trend Negative

52-week position 76%

mid-range

Momentum

relative strength

Strong

1-month return −2%

trailing

6-month return +6%

trailing

YTD return +5%

this year

Relative strength −1%

vs S&P · 6-mo

Sentiment

smart money

Very Bullish

Trend (MA cross) Golden cross

50d $33 › 200d $33 — 50d above 200d

Institutional flow Accumulating

47 of 255 funds reported for Jun 30 · net +151.3K sh shares · +10 new

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

10.90% of float · ▼ -7.4% MoM · 8.6 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

255 holders — near 3-yr high, broad support

Squeeze score 77

high risk · 0–100

Fundamentals

Strong

Revenue growth +3024%

Y/Y

EPS growth +62%

Y/Y

Free cash flow $-73.5M

Balance sheet $112.8M

net cash

Quant / Vol

risk profile

Very High

Volatility 48%

annualized · 1-yr

Max drawdown −27%

past year

ATR 4.3%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy

1 · 2 · 3

50 / 200-day cross

Golden cross Bullish

Price vs 200-day avg

+11% Bullish

Price vs 50-day avg

+10% Bullish

RSI (14)

54 Neutral

MACD trend

Negative Bearish

52-week position

76% Neutral

Market signals — smart money & positioning

Bullish · 4 of 6

Trend (MA cross) Golden cross

50d $33 › 200d $33 — 50d above 200d

Institutional flow Accumulating

47 of 255 funds reported for Jun 30 · net +151.3K sh shares · +10 new

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

10.90% of float · ▼ -7.4% MoM · 8.6 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

255 holders — near 3-yr high, broad support

Price context

position in its 52-week range

52-wk low $22 Now $36 · 76% 52-wk high $41

vs 200-day avg +11% vs 50-day avg +10% 50-day above 200-day golden cross

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from its earnings releases, calls, and filings

Metric	Latest	Period	YoY
cash, cash equivalents and marketable securities	1.05B	Full Year 2025	—

Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
IDYA IDEAYA Biosciences, Inc. this stock	$3.13B	+4.6%	+3024.4%	—	10.9%
ONC BeOne Medicines Ltd.	$472.90B	+8.8%	+22179.2%	962.4	0.1%
VRTX Vertex Pharmaceuticals Inc / Ma	$124.46B	+8.2%	+46.2%	29.1	2.0%
REGN Regeneron Pharmaceuticals, Inc.	$72.88B	-9.8%	+20.8%	17.0	3.3%
ARGX Argenx SE	$54.57B	+3.7%	—	—	2.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

260

% held: 109.8%
Reported: 47 of 255
Top holder: FMR LLC

Held Float

View

Held by Funds

Fund positions

240

View

Short & Settlement

Short Interest Falling

Shares short

9.6M

Days to cover: 8.6d
Change: -761.4K sh

View

Short Volume

Short vol %

37%

As of: Jul 29, 2026

Short Total

View

Fails to Deliver

FTD shares

100.7K

Value: $3.7M
As of: Jun 30, 2026

View

Off-Exchange

Off-exchange %

45.0%

Week of: May 4, 2026

Off-exch Lit

View

Financials

Revenue (FY)

$218.7M

Net income (FY): $-113.7M
EPS diluted: $-1.28

View

Filings

SEC Filings

Latest

Investor Event Transcript

Filed: Jun 30, 2026
This year: 16

View

Proposed Sales

Value

$3.0M

Shares: 75.0K
Filed: Aug 26, 2024

View

Earnings & Events

Earnings Calls

Last call

Jun 4, 2026

View

	5D	20D	120D	MTD	YTD
IDYA	+2.0%	-1.6%	+6.2%	-3.0%	+4.6%
SPY	-1.0%	0.0%	+7.4%	-0.8%	+8.6%
vs SPY	+3.0%	-1.6%	-1.3%	-2.2%	-4.0%

IDYA · IDEAYA Biosciences, Inc.

Price & Indicators

Up next

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance